Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working more...
Socket Mobile Ships its Millionth scanner
Socket Mobile Ships its Millionth scanner PR Newswire NEWARK, Calif. , April 12, 2022 /PRNewswire/ — Socket Mobile, Inc. (NASDAQ: SCKT), a leading provider of data capture and delivery solutions designed to enhance workplace productivity, is more...
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) (“Acer”) and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief”), today announced the presentation of data evaluating the more...
DLH Holdings Corp. (DLHC) Stock Moves -1.25%: What You Should Know
DLH Holdings Corp. (DLHC) closed at $17.34 in the latest trading session, marking a -1.25% move from the prior day. This move was narrower than the S&P 500’s daily loss of 1.69%. Meanwhile, the Dow more...
Microbot Medical to Review Recent Progress During Needham’s Virtual Healthcare Conference
HINGHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview more...
Quantum Reports Preliminary Revenue Results for Fourth Quarter Fiscal 2022 and Provides Update on Debt Arrangements
Quantum Reports Preliminary Revenue Results for Fourth Quarter Fiscal 2022 and Provides Update on Debt Arrangements PR Newswire SAN JOSE, Calif. , April 11, 2022 /PRNewswire/ — Quantum Corporation (NASDAQ: QMCO) announced today preliminary revenue more...
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD PR Newswire AUSTIN, Texas , April 11, 2022 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), more...
Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022
BILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May more...
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity more...
SeaSpine Announces Full Commercial Launch of the Reef® TA (TLIF Articulating) Interbody System
CARLSBAD, Calif., April 11, 2022 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of more...